التفاصيل البيبلوغرافية
العنوان:
Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies
المؤلفون:
Jill Gluskin , Taryn M. Boucher , Nancy E. Kemeny , Ariel Aguilo , Joanne F. Chou , Andrea Cercek , Louise Catherine Connell , Diane Reidy-Lagunes , Marinela Capanu , Michael I. D’Angelica
المصدر:
Journal of Surgical Oncology . 114:655-663
بيانات النشر:
Wiley, 2016.
سنة النشر:
2016
مصطلحات موضوعية:
Oncology , medicine.medical_specialty , Colorectal cancer , business.industry , General Medicine , medicine.disease , Systemic therapy , Oxaliplatin , Irinotecan , 03 medical and health sciences , 0302 clinical medicine , Hepatic arterial infusion , Refractory , Tumor progression , 030220 oncology & carcinogenesis , Internal medicine , medicine , Surgery , 030212 general & internal medicine , Progression-free survival , business , medicine.drug
الوصف:
Background and Objectives To evaluate the role of hepatic arterial infusion (HAI) in patients with metastatic colorectal cancer (mCRC) liver metastases (LM) refractory to oxaliplatin, irinotecan, and fluorouracil-based treatments. Methods A search identified patients with mCRC treated after tumor progression on at least three standard systemic therapies. Results One hundred and ten patients met criteria for inclusion (i.e., progression on at least three standard agents). Fifty seven patients had LM-only and 53 patients had LM and low volume extrahepatic metastases (LME). Patients with LM-only and LME had a response rate (RR) of 33% and 36%, median survival of 20 months and 11.4 months, respectively. Patients with LM-only had progression free survival of 6 months and hepatic progression free survival of 7.56 months. In a secondary analysis, 46 patients were RECIST-refractory to all standard therapies: LM-only (n = 24) and LME (n = 22). LM-only and LME had a RR of 29% and 36%, and median survival 17.2 months and 9.1 months, respectively. Conclusions Patients with refractory mCRC LM can achieve a response to HAI resulting in antitumor activity and improvement in survival. Responses are rarely seen in such heavily treated patients with systemic therapy alone, suggesting a regional directed approach is useful. J. Surg. Oncol. 2016;114:655–663. © 2016 Wiley Periodicals, Inc.
تدمد:
0022-4790
URL الوصول:
https://explore.openaire.eu/search/publication?articleId=doi_________::798e57c8ea28305f722c3fc392735b38 https://doi.org/10.1002/jso.24399
حقوق:
OPEN
رقم الأكسشن:
edsair.doi...........798e57c8ea28305f722c3fc392735b38
قاعدة البيانات:
OpenAIRE
